| Hazard Information | Back Directory | [Uses]
Livmoniplimab (ABBV-151) is a monoclonal antibody against GARP/TGF-β1 that can inhibit the release of active TGF-β1. Livmoniplimab has anti-tumor activity in colon cancer mice. Livmoniplimab can be used for the study of locally advanced or metastatic solid tumors[1][2]. | [in vivo]
Livmoniplimab (250 μg; three times a week; 3 weeks; i.p.) exhibits anti-tumor activity in colon cancer mice[2]. | Animal Model: | 7-week-old female B-hGARP mice subcutaneously inoculated with MC38 mouse colon cancer cells[2]. | | Dosage: | 250 μg | | Administration: | Intraperitoneal injection (i.p.); three times a week; 3 weeks | | Result: | Resulted in 34.3% tumor growth inhibition. |
| [References]
[1] Tindall RR, et al. The TGF-β superfamily as potential therapeutic targets in pancreatic cancer. Front Oncol. 2024 Mar 4;14:1362247. DOI:10.3389/fonc.2024.1362247
[2] Guo J, et al. A novel GARP humanized mouse model for efficacy assessment of GARP-targeting therapies. Int Immunopharmacol. 2024 Mar 30;130:111782. DOI:10.1016/j.intimp.2024.111782 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|